Dynavax Technologies Co. (NASDAQ:DVAX) Shares Sold by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank lessened its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 78.1% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 25,880 shares of the biopharmaceutical company’s stock after selling 92,157 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Dynavax Technologies were worth $288,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Renaissance Technologies LLC lifted its stake in Dynavax Technologies by 2.2% in the 2nd quarter. Renaissance Technologies LLC now owns 2,478,178 shares of the biopharmaceutical company’s stock worth $27,830,000 after purchasing an additional 53,600 shares in the last quarter. Great Point Partners LLC lifted its position in Dynavax Technologies by 87.7% during the second quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company’s stock worth $26,660,000 after buying an additional 1,109,080 shares in the last quarter. Millennium Management LLC purchased a new stake in Dynavax Technologies in the 2nd quarter valued at $17,615,000. Mizuho Markets Americas LLC increased its stake in shares of Dynavax Technologies by 17.4% in the 3rd quarter. Mizuho Markets Americas LLC now owns 1,379,582 shares of the biopharmaceutical company’s stock worth $15,369,000 after acquiring an additional 204,475 shares during the last quarter. Finally, Bank of Montreal Can raised its holdings in shares of Dynavax Technologies by 8.3% during the 3rd quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company’s stock worth $11,848,000 after acquiring an additional 82,449 shares during the period. 96.96% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies Price Performance

Dynavax Technologies stock opened at $12.85 on Monday. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. Dynavax Technologies Co. has a 52-week low of $9.74 and a 52-week high of $15.01. The firm has a market cap of $1.69 billion, a PE ratio of 98.85 and a beta of 1.33. The company’s 50 day moving average is $11.85 and its two-hundred day moving average is $11.44.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $29.00 price target on shares of Dynavax Technologies in a research note on Friday, November 8th.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.